ISSUE 1525
| The full article is available to subscribers | Subscriber Login |
The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.1,2
STANDARD TREATMENT — Plaque psoriasis is a chronic, inflammatory, immune-mediated skin condition. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac, and others) are alternatives that can be used alone or in combination with topical corticosteroids.3 For patients with moderate to severe disease, systemic options include
... more- Secukinumab (Cosentyx) for psoriasis. Med Lett Drugs Ther 2015; 57:45.
- Ixekizumab (Taltz) – a second IL-17A inhibitor for psoriasis. Med Lett Drugs Ther 2016; 58:59.
- Calcipotriene/betamethasone foam (Enstilar) for psoriasis. Med Lett Drugs Ther 2016; 58:48.
- Drugs for psoriasis. Med Lett Drugs Ther 2015; 57:81.
- TN Canavan et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 2016; 17:33.
- A Chiricozzi et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf 2016; 15:1653.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Immediate Online access to current issue and archives from 1988 to the present
- Mobile access to our mobile site and free apps for iOS, Android and Kindle
- FREE online per issue CME/CE
Article code: 1525b
Electronic, downloadable article - $25
